Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-127

there was fundamentally nothing in the quarterly that we did not already know...

We were told some time ago by Derek there was increased regulatory hoops to jump through for countries to approve Eugeni.. no surprise it was laid out in greater details in the Quarterly so the the back seat drivers could be spoon fed the difficulties they are facing now.

We already knew there were modest sales only to Ellume and Anteobind in general... so no surprise on the figures from the quarterly.'

So what is new in the quarterly ?

Entry into the US via Ellume's "consultants"
Sepsis well on track
Collab 8 hopefully looking likely to sign early 2022
COVID Flu mulitplex about to go clinical

Is it disappointing the new European regulatory requirements are causing delays ? Sure.. for those that say we missed millions of sales well we must remember we did not make a single standalone test and just go and flog it there is a whole system/platform attached to it.. there has been some myopic criticism imo of the strategy or lack thereof.. and here is why i think this is the case..

Anteo is developing a POC diagnostics Platform for global distribution for multiple tests ( i wont list the possible tests). They are not developing a standalone single test/s unit like many other manufacturers. IMVHO They are creating a point of difference with EUGENI and targeting tests that are notoriously difficult and have unmet needs at the POC. i am a firm believer that Eugeni will bring POC tests to the market that were once never thought possible and Revolutionise POC testing and put some pressure on traditional lab testing in the years to come. They will also have the potential to reduce testing costs significantly as we all know PCR testing is expensive.

Will Anteo fail because they didn't get their Covid test to market sooner ? NO. Covid was merely their tipping point to speed up the transition from R&D to manufacturer, which by the way, WAS and IS the main strategy of the company. Its strategy is not to be a standalone test manufacturer but rather a global POC diagnostics platform provider.

This myopic view of just this one COVID test and TGA approval imvho is detracting from the BIG picture and the COVID test will not make or break Anteo.. They have far too many other larger markets lined up just around the corner..